[go: up one dir, main page]

BRPI0920976A2 - Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular. - Google Patents

Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular.

Info

Publication number
BRPI0920976A2
BRPI0920976A2 BRPI0920976-0A BRPI0920976A BRPI0920976A2 BR PI0920976 A2 BRPI0920976 A2 BR PI0920976A2 BR PI0920976 A BRPI0920976 A BR PI0920976A BR PI0920976 A2 BRPI0920976 A2 BR PI0920976A2
Authority
BR
Brazil
Prior art keywords
compositions
restoration methods
vascular lesion
infusion area
area perfusion
Prior art date
Application number
BRPI0920976-0A
Other languages
English (en)
Inventor
Andrew Pecora
Robert Pretti
Original Assignee
Amorcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorcyte Inc filed Critical Amorcyte Inc
Publication of BRPI0920976A2 publication Critical patent/BRPI0920976A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0920976-0A 2008-12-03 2009-12-02 Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular. BRPI0920976A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11955208P 2008-12-03 2008-12-03
US16985009P 2009-04-16 2009-04-16
PCT/US2009/066354 WO2010065601A1 (en) 2008-12-03 2009-12-02 Infarct area perfusion-improving compositions and methods of vascular injury repair

Publications (1)

Publication Number Publication Date
BRPI0920976A2 true BRPI0920976A2 (pt) 2015-08-18

Family

ID=42231331

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920976-0A BRPI0920976A2 (pt) 2008-12-03 2009-12-02 Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular.

Country Status (10)

Country Link
US (1) US9034316B2 (pt)
EP (1) EP2367432B1 (pt)
JP (2) JP5705127B2 (pt)
CN (1) CN102245189B (pt)
BR (1) BRPI0920976A2 (pt)
CA (1) CA2743255C (pt)
ES (1) ES2640587T3 (pt)
RU (2) RU2497532C2 (pt)
WO (1) WO2010065601A1 (pt)
ZA (1) ZA201104059B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
SG10201402289VA (en) 2009-05-11 2014-07-30 Berg Llc Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
GB2487339A (en) * 2009-10-23 2012-07-18 Amorcyte Inc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
ES2654994T3 (es) * 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
AU2015201990B2 (en) * 2010-08-12 2017-06-22 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
CA2857640C (en) 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
WO2014110180A1 (en) 2013-01-12 2014-07-17 Cesca Therapeutics, Inc. Rapid infusion of autologous bone marrow derived stem cells
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CA2923216A1 (en) * 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
CN107072189B (zh) 2014-07-08 2021-07-20 罗廷灿 用于改善干细胞稳定性的组合物
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20220378301A1 (en) * 2016-01-04 2022-12-01 Corflow Therapeutics Ag Intracoronary characterization of microvascular obstruction (mvo) and myocardial infarction
CN116606861A (zh) 2016-06-07 2023-08-18 摩登纳特斯有限公司 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途
EP3630133A4 (en) 2017-05-26 2021-01-20 Steminent Biotherapeutics Inc. THERAPY FOR POLYGLUTAMINE (POLYQ) DISEASES
RS63389B1 (sr) 2017-10-31 2022-08-31 Astrazeneca Ab Lipidne nanočestice za isporuku modifikovane rnk koja enkodira polipeptid vegf-a
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
US11922630B2 (en) * 2019-01-25 2024-03-05 The Johns Hopkins University Predicting atrial fibrillation recurrence after pulmonary vein isolation using simulations of patient-specific magnetic resonance imaging models and machine learning
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN111281400B (zh) * 2020-01-22 2022-08-19 首都医科大学宣武医院 借助于非接触式血管可视化设备的辅助操作装置及方法
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
CA3195653A1 (en) 2020-10-14 2022-04-21 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
CN112891631B (zh) * 2021-01-29 2021-12-03 江南大学 一种植物源导管及其在修复神经损伤中的应用
CN115205294B (zh) * 2022-09-16 2022-11-22 杭州脉流科技有限公司 一种基于多模型融合的缺血性脑卒中梗死评估装置和方法
CN117305241B (zh) * 2023-11-28 2024-03-19 上海兴瑞一达生物科技有限公司 一种hiPSCs诱导分化为NK细胞的方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5726152A (en) 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
WO1993025216A1 (en) 1992-06-08 1993-12-23 Becton, Dickinson And Company Human primitive stem cells
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
US5628761A (en) * 1994-07-08 1997-05-13 Rizik; David G. Guide wire passage creation device
US20030113304A1 (en) 1995-06-07 2003-06-19 The Trustees Of Columbia University Selective tissue site revascularization by combined focal injury and hematopoietic stem cell introduction
US5810836A (en) * 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US8075880B2 (en) 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
JP2002500879A (ja) 1998-01-23 2002-01-15 イムクローン システムズ インコーポレーテッド 幹細胞の精製ポピュレーション
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
AU4323599A (en) 1998-05-29 1999-12-13 Instituto Superiore Di Sanita Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
IL141683A0 (en) 1998-08-31 2002-03-10 Univ New York Stem cells bearing an fgf receptor on the cell surface
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
US6287265B1 (en) 1999-06-23 2001-09-11 Cindy L. Gleason Blood collection kit
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
AU1100001A (en) 1999-10-29 2001-05-14 Children's Hospital Of Los Angeles Gammac negative hematopoietic progenitor cells
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
AU2001250966A1 (en) 2000-03-23 2001-10-03 Stem Cells, Inc. Pluripotential stem cells
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20020098167A1 (en) 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002013760A2 (en) 2000-07-31 2002-02-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20040014706A1 (en) 2000-09-11 2004-01-22 Franz-Werner Kluxen Use of carp inhibitors for the treatment of heart diseases
JP2005508831A (ja) 2000-10-02 2005-04-07 ザ スクリプス リサーチ インスティテュート 血管新生促進のための方法および組成物
FR2819265B1 (fr) 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
EP1361896A2 (en) 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
EP1381410A2 (en) 2001-04-09 2004-01-21 Medtronic, Inc. Methods of isolating blood components using a centrifuge and uses thereof
ITTO20010517A1 (it) 2001-05-31 2002-12-01 Giulio Alessandri Cellule progenitrici vascolari umane.
CA2457694A1 (en) 2001-08-09 2003-02-20 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
KR101001119B1 (ko) 2001-11-21 2010-12-14 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 인간 단핵 식세포성 백혈구의 제조 방법
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
AU2002360741B2 (en) 2001-12-21 2008-07-17 Immunex Corporation Endothelial stem cells, populations, methods of isolation and use thereof
US7172758B2 (en) 2002-01-29 2007-02-06 Colb A Mark Endothelialization of vascular surfaces
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2003242976A1 (en) 2002-07-16 2004-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of implanting mesenchymal stem cells for tissue repair and formation
PL216193B1 (pl) 2002-07-25 2014-03-31 Scripps Research Inst Wyizolowana, ssacza, pochodząca ze szpiku kostnego linia populacji niezróżnicowanych krwiotwórczych komórek macierzystych
AU2003270051A1 (en) 2002-08-29 2004-03-19 Baylor College Of Medicine Heart derived cells for cardiac repair
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2003275326A1 (en) * 2002-09-30 2004-04-23 Massachussetts Eye And Ear Infirmary In vitro culture of tissue structures
US20040136973A1 (en) 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
CA2547899C (en) 2002-12-05 2014-04-15 Case Western Reserve University Cell-based therapies for ischemia
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
US20040197310A1 (en) 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
EP1601248A4 (en) 2003-02-13 2010-01-27 Anthrogenesis Corp USE OF CORDIAL BLOOD FOR THE TREATMENT OF SUBJECTS SUFFERING FROM A DISEASE, A SUFFERING OR A DISORDER
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US7863043B2 (en) 2004-02-11 2011-01-04 Aldagen, Inc. Stem cell populations and methods of use
US20050232905A1 (en) 2004-03-26 2005-10-20 Yeh Edward T Use of peripheral blood cells for cardiac regeneration
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
JP2006115771A (ja) 2004-10-22 2006-05-11 Kyoto Univ 骨格筋由来の心筋幹細胞
US20060165667A1 (en) * 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
KR20070112205A (ko) 2005-02-28 2007-11-22 리제네텍 인코포레이티드 심장 조직 재생용 조성물 및 방법
US20070059288A1 (en) 2005-03-31 2007-03-15 Dinsmore Jonathan H Treatment for heart disease
PL2441461T3 (pl) 2005-11-07 2014-11-28 Pecora & Co Llc Kompozycje i sposoby naprawy uszkodzenia naczyniowego
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
US20080118977A1 (en) 2006-11-22 2008-05-22 Institut De Recherche En Hematologie Et Transplantation Process to cary out a cellular cardiomyoplasty
GB2487339A (en) * 2009-10-23 2012-07-18 Amorcyte Inc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency

Also Published As

Publication number Publication date
CA2743255A1 (en) 2010-06-10
JP2013166803A (ja) 2013-08-29
RU2013136170A (ru) 2015-02-10
EP2367432B1 (en) 2017-08-30
CN102245189A (zh) 2011-11-16
EP2367432A1 (en) 2011-09-28
US20100143317A1 (en) 2010-06-10
JP2012510521A (ja) 2012-05-10
CN102245189B (zh) 2015-06-17
CA2743255C (en) 2014-02-18
RU2011127184A (ru) 2013-01-10
HK1163542A1 (en) 2012-09-14
ES2640587T3 (es) 2017-11-03
US9034316B2 (en) 2015-05-19
RU2550959C2 (ru) 2015-05-20
ZA201104059B (en) 2012-02-29
EP2367432A4 (en) 2012-05-02
WO2010065601A1 (en) 2010-06-10
JP5705127B2 (ja) 2015-04-22
RU2497532C2 (ru) 2013-11-10

Similar Documents

Publication Publication Date Title
BRPI0920976A2 (pt) Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular.
BRPI0919884A2 (pt) cateter de perfusão de oclusão
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0920030A2 (pt) agente de oclusão do tecido
EP2204153A4 (en) TATTOO CHAIR
EP2327448A4 (en) defibrillation catheter
EP2068730A4 (en) SURGICAL CATHETERS
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
PL4066787T3 (pl) Protetyczna zastawka serca i urządzenie wprowadzające
EP2138200A4 (en) SUCTION CATHETER OF A THROMBUS
EA201000984A1 (ru) Синтетические тритерпеноиды и способы их применения в лечении заболеваний
BRPI0812861A2 (pt) Conexão luer de segurança
ES2465478T8 (es) Composiciones farmacéuticas que comprenden brivaracetam
ATE536905T1 (de) Dilatationskatheter
IT1392897B1 (it) Frazione piastrinica derivante da sangue placentare
SM200800007B (it) Apparato medicale di iniezione
HRP20181559T1 (hr) Štrcaljka s integriranim ventilskim muškim luer lock konektorom
EP2052757A4 (en) MEDICAL CAPSULE
EP2216067A4 (en) CATHETER
IT1396733B1 (it) Protesi vascolare perfezionata e relativo metodo di realizzazione.
FR2927632B1 (fr) Cornee et muqueuse reconstruites.
BRPI1015432A2 (pt) "composição e método para melhorar a saúde vascular"
BRPI0925034A2 (pt) Composição farmacêutica intravenosa e respectivos usos.
DE602007008179D1 (de) Führungsdrahtstruktur mit medizinischem Führungsdraht
BRPI0912246A2 (pt) Composto, composição farmacêutica, e, usos de uma composição farmacêutica e de um composto.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]